Certara®, the global provider of biosimulation, has announced that it has launched the COVID-19 Clinical Outcomes Database to provide up-to-date information on the results of COVID-19 clinical trials and observational studies, worldwide, the company said.
The database captures publicly available study results to quantify and compare the impact of treatments. It is funded by the COVID-19 Therapeutics Accelerator, which was launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, with additional funding from a range of donors.
The COVID-19 Clinical Outcomes Database will help to determine the viability of potential therapeutics and vaccines for COVID-19 by using relevant data from more than 500 registered COVID-19 studies, worldwide, over the next three months. It currently contains results from 68 studies that are testing therapeutics that include chloroquine, hydroxychloroquine, remdesivir, lopinavir/ritonavir, and favipiravir.
These studies have been completed and results are available. The database captures all outcome data on safety and efficacy, as well as the impact of risk factors such as age, sex, and co-morbidities. It is curated to address the heterogeneity and variability in datasets across COVID-19 studies.
Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs approved by the US FDA in the past six years were supported by Certara software or services. Its clients include 1,600 global biopharmaceutical companies, academic institutions, and key regulatory agencies across 60 countries. For more information, visit www.certar Related Articles